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Myeloid-derived suppressor cells (MDSCs) promote tumor immune evasion and favor
tumorigenesis by activating various tumor-promoting downstream signals. MDSC
expansion is evident in the circulation and tumor microenvironment of many solid
tumors including colorectal cancer (CRC). We have recently reported the transcriptomic
profiles of tumor-infiltrating MDSCs in CRC patients and uncovered pathways,
which could potentially assist tumor progression. In this study, we sorted different
subsets of circulating MDSCs in CRC patients and investigated their transcriptomic
profiles in order to disclose pathways, which could potentially contribute to disease
progression. The sorted subsets included polymorphonuclear/granulocytic MDSCs
(PMN-MDSCs), immature MDSCs (I-MDSCs), and monocytic MDSCs (M-MDSCs). Our
functional annotation analyses revealed that multiple pathways including DNA damage-,
chemotaxis-, apoptosis-, mitogen-activated protein kinase-, transforming growth factor
β-, andmyeloid differentiation–related transcripts were higher in PMN-MDSCs, compared
with monocytic antigen-presenting cells (APCs) or I-MDSCs. Furthermore, genes related
to Janus kinase (JAK)–signal transducer and activator of transcription (STAT) were
also elevated in PMN-MDSCs. These data suggest that upregulation of JAK-STAT
pathway could trigger multiple downstream targets in PMN-MDSCs, which favor
tumor progression. Additionally, we found that pathways including phosphatidyl
inositol 3-kinase (PI3K), interleukin 6, and TGF-β in M-MDSCs and cell cycle–related
pathways in I-MDSCs were upregulated, compared with monocytic APCs. Moreover,
acetylation-related genes were upregulated in both PMN-MDSCs and M-MDSCs. This
latter finding implicates that epigenetic modifications could also play a role in the
regulation of multiple tumor-promoting genes in PMN-MDSCs and M-MDSCs. Taken
together, this study reveals various signaling pathways, which regulate the function
of MDSC subsets in the circulation of CRC patients. However, functional studies are
warranted to support these findings.
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INTRODUCTION
Colorectal cancer (CRC) ranks second in terms of mortality
and third in terms of incidence among all cancers in 2018 (1).
Immune cells play an indispensable role in tumorigenesis and
progression of CRC (2, 3). The infiltration of CD3+CD8+ T
cells into the CRC tumor microenvironment (TME) has been
reported as an indicator of disease prognosis; higher CD3+CD8+
T-cell infiltrates have been associated with favorable prognosis
(2). Apart from lymphoid cells, the involvement of myeloid
cells in the enhancement of metastatic cascade in solid tumors
has also been reported (4). Myeloid-derived suppressor cells
(MDSCs) play a predominant role in the survival of tumor
cells by providing an immunosuppressive shield to protect
them from host immune response and facilitate resistance to
immunotherapy (4). It has been shown that MDSCs favor the
survival of regulatory T cells within the TME, which are a key
component of the immunosuppressive mediators that attenuate
functionality of tumor-reactive T cells (5) and also induce the
differentiation of fibroblasts to cancer-associated fibroblasts (6).
Increase in circulating MDSC in higher stages of cancer has been
reported to be correlated with worse survival rates and resistance
to immune checkpoint blockade (7–9). These reports suggest that
targeting MDSCs improves the host-immune responses against
malignant cells and also enhances the efficiency of immune
checkpoint blockade therapy.
Different MDSC subsets can suppress antitumor immune
responses via distinct mechanisms (10). Monocytic MDSCs
(M-MDSCs) can inhibit T-cell activation via arginase 1
(ARG1)–, inducible nitric oxide synthase–, and transforming
growth factor β (TGF-β)–mediated signaling pathways (11, 12).
In contrast, polymorphonuclear/granulocytic MDSCs (PMN-
MDSCs), which are usually the most predominant MDSC subset
in most cancers, can release high levels of reactive oxygen species
and inhibit T-cell stimulation/activation in an antigen-specific
manner (13–15). The presence of immature MDSCs (I-MDSCs)
in tumor issues and peripheral blood of cancer patients and
their relationship with poor prognosis has been reported (16);
however, distinct immunosuppression-mediatedmechanisms for
I-MDSCs have not been yet elucidated.
We have previously reported that PMN-MDSCs and I-MDSCs
were expanded in the CRC TME, whereas only PMN-MDSCs
were expanded in circulation of CRC patients (3). Importantly,
we found that the levels of circulating PMN-MDSCs correlated
with tumor stage and histological grade in CRC patients (3).
In this study, we investigated the transcriptomic analyses to
reveal signaling pathways and biological mechanisms regulated
by MDSC subsets in the circulation of CRC patients. We
performed comparative analyses of the transcriptomic profiles of
the different myeloid subsets, compared to monocytic antigen-
presenting cells (APCs).
We found that multiple cancer-related pathways were
upregulated in the different myeloid cell subsets. Interestingly,
we found that acetylation-related genes were upregulated in
both M-MDSCs and PMN-MDSCs, which could play a role
in the transcriptional regulation of genes favoring tumor
progression and metastasis of malignant cells. Collectively, our
TABLE 1 | Characteristic features of study populations.
CRC patients
Number 4
Age 73 (48–96)†
Gender (male:female) 3:1
TNM stage
IIA 3
IV 1 (patient 9)
Histological grade
G2–moderately differentiated All samples
†
Data shown represent median (range).
CRC, colorectal cancer.
data reveal that tumor-promoting signaling pathways were
upregulated in circulating myeloid suppressive cell subsets of
CRC patients, suggesting their contribution to carcinogenesis
and tumor progression. However, these data lack functional
studies due to limited cell numbers following FACS sorting,
and further confirmation studies are needed in a larger number
of patients.
MATERIALS AND METHODS
Sample Collection and Storage
Peripheral blood samples were obtained from 4 treatment-
naive CRC patients (No. 7, 9, 12, and 16) at Hamad Medical
Corporation, Doha, Qatar. Table 1 shows the clinical and
pathological characteristics of participating patients. All
patients provided written informed consent prior to sample
collection. Peripheral blood mononuclear cells (PBMCs)
were isolated from fresh blood using Histopaque gradient
centrifugation and stored, as previously described (17).
This study was performed under ethics approvals from
Hamad Medical Corporation, Doha, Qatar (protocol no.
MRC-02-18-012), and Qatar Biomedical Research Institute,
Doha, Qatar (protocol no. 2018-018). All experiments
were executed in accordance with relevant guidelines
and regulations.
Multiparametric Flow Cytometry
Isolated PBMCs were stained as previously described (17, 18).
Briefly, cells were stained with antibodies against CD33–
fluorescein isothiocyanate (clone HIM3-4; BD Biosciences,
Oxford, UK), HLA DR–phycoerythrin (clone G46-6; BD
Biosciences), CD14–phycoerythrin–Cy7 (clone M5E2; BD
Biosciences), and CD15–allophycocyanin (clone HI98;
BioLegend, San Diego, CA, USA). 7-AAD viability dye
(eBioscience, San Diego, CA, USA) was used to identify live cells.
The cells were prepared for analyses and sorting as previously
described (17, 18) Minimal sorter-induced cell stress was
ensured following applicable measures, as previously described
(19). FlowJo V10 software (FlowJo, Ashland, OR, USA) was used
to perform data analyses.
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Library Preparation
Study design and pipeline for bioinformatics analyses were
performed, as we have previously described (18). Briefly, 1,000
I-MDSCs, M-MDSCs, PMN-MDSCs, and monocytic APCs cells
were sorted with high purity from PBMCs of CRC patients. The
cDNA libraries were prepared from sorted cells using QIAseq FX
Single Cell RNA Library Kit (Qiagen, Hilden, Germany), as we
have previously reported (20). The quality passed libraries were
subjected to sequencing using Illumina HiSeq 4000 as previously
described (20).
Transcriptomic Data Analyses
Raw data obtained from Illumina HiSeq 4000 in the form of
FASTQ files were analyzed on CLC Genomics Workbench-12
(Qiagen), as previously described (18). Briefly, paired end reads
were quality-trimmed and aligned to the hg19 human reference
genome, and the read count was calculated as TPMs (transcripts
per million) mapped reads. Default settings were applied to
analyze the differential expression between the study subsets. The
Z score was calculated for all the differentially expressed genes,
with P < 0.05, and used for the construction of heat maps for
data visualization.
Functional Annotation Analyses
The Gene Ontology Biological Process (GO BP), Kyoto
Encyclopedia of Genes and Genomes (KEGG), and BioCarta
network analyses (21, 22) were performed on Database
for Annotation, Visualization and Integrated Discovery
platform (v.6.8, https://david.ncifcrf.gov/), as previously
described (18). We focused on functional networks in
upregulated/downregulated genes. The gene data from
functional analyses were presented as heat plots. Protein–
protein interaction networks for selected signaling pathways
were obtained from STRING, a web-based online tool
for protein–protein interaction networks and functional
enrichment analyses (https://string-db.org/) (23). Principal
component analysis (PCA) plots were generated using TPMs of
differentially expressed genes on iDEP.91 (integrated Differential
Expression and Pathway analysis, http://bioinformatics.
sdstate.edu/idep/), a web-based online analyses tool, using
default settings.
RESULTS
Myeloid Subsets in the Circulation of CRC
Patients
We have previously reported that levels of PMN-MDSCs were
higher in the circulation of CRC patients, compared with
healthy donors (3). Additionally, these PMN-MDSCs showed an
upregulation of ARG1, which is an indicator of their suppressive
function (3). Furthermore, we have previously reported that
the levels of PMN-MDSCs and I-MDSCs are higher in the
CRC TME (3). Using monocytic APCs as controls, our recent
study on the transcriptomic characteristics of the different
MDSC subsets in the TME of CRC patients has provided
novel insights into the epigenetic mechanisms including DNA
methylation/posttranslational histone modifications and other
signaling pathways regulating their transcriptional profile and
function (18). Despite the phenotypic differences between
the various MDSC subsets, including granulocytic (PMN-),
monocytic (M-), and immature (I-) MDSCs, they all possess
an immunosuppressive activity and lack the expression of
HLA-DR. On the contrary, monocytic APCs express HLA-
DR; therefore, they were used as controls for the other three
MDSC subsets.
In this study, we sorted the different myeloid cell
subpopulations including PMN-MDSCs (CD33+HLA-DR−/low
CD14−CD15+), I-MDSCs (CD33+HLA-DR−/lowCD14−
CD15−), M-MDSCs (CD33+HLA-DR−/lowCD14+CD15−),
and monocytic APCs (CD33+HLA-DR+CD14+) from the
circulation of CRC patients to investigate their transcriptomic
characteristics, which could potentially contribute to disease
progression. The gating strategy for sorting these subsets is
shown in Figure 1. Comparative analyses were then performed
from the libraries generated from the different sorted myeloid
cell subpopulations, including PMN-MDSCs vs. monocytic
APCs, PMN-MDSCs vs. I-MDSCs, M-MDSCs vs. monocytic
APCs and I-MDSCs vs. monocytic APCs.
Genes Associated With Janus
Kinase–Signal Transducer and Activator of
Transcription, Transcriptional Regulation,
and Histone Acetylase Were Upregulated
in Circulating PMN-MDSCs, Compared
With Monocytic APCs of CRC Patients
We have previously reported that DNA methylation- and
histone deacetylase (HDAC) binding-related genes were
downregulated in tumor-infiltrating PMN-MDSCs, compared
with PMN-MDSCs in normal colon tissues of CRC patients
(18). Here, we analyzed the transcriptomic profiles of PMN-
MDSCs, compared with monocytic APCs in the circulation
of four CRC patients (No. 7, 9, 12, and 16). The hierarchal
clustering of differentially expressed transcripts showed 1,912
upregulated and 2,412 downregulated transcripts in PMN-
MDSCs, compared with monocytic APCs (fold of change >2
and P value cutoff <0.05) (Figures 2A,B). The PCA from
the TPMs showed that the PMN-MDSCs and monocytic
APCs from four patient samples were clustered separately,
representing the significant differences in the overall gene
expression (Supplementary Figure 1A). The PCA plot also
showed high variability in the expression of PMN-MDSCs
among the individuals, but it should not affect the downstream
analyses due to the cluster separation of PMN-MDSCs and
monocytic-APCs (Supplementary Figure 1A). Functional
annotation analyses revealed that upregulated pathways
in PMN-MDSCs were related to DNA damage (4 genes),
chemotaxis (4 genes), transcriptional regulation (114 genes),
signal transduction (6 genes), cellular defense response (8
genes), and Histone H4 acetylation (7 genes) (Figures 2C,D;
Table 2). Interestingly, the genes responsible for apoptosis (21
genes), mitogen-activated protein kinase (MAPK) activity (8
genes), myeloid differentiation (6 genes), negative regulation of
transcription (54 genes), and Wnt signaling pathway (10 genes)
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FIGURE 1 | Gating strategy of I-MDSCs, M-MDSCs, PMN-MDSCs, and monocytic APCs. Peripheral blood mononuclear cells were isolated from four CRC patients
(7, 9, 12, and 16). Flow cytometric plots show the levels of I-MDSCs (denoted as I), M-MDSCs (denoted as M), and PMN-MDSCs (denoted as PMN) gated on
CD33+HLA-DR−/low and monocytic APCs gated on CD33+HLA-DR+ cells. Sorted pure myeloid cell subsets were used for RNA-Seq (A). Representative flow
cytometric plots show the sorting purity of CD33+HLA-DR+CD14+ monocytic APCs (B).
were downregulated in PMN-MDSCs (Figures 2C,E; Table 2).
Moreover, genes involved in Wnt signaling pathway formed a
PPI enrichment with P value 0.116, including 10 nodes and 4
edges (Supplementary Figure 2A).
Reports show that both leptin (LEP) (24) and growth hormone
1 (GH1) (25) could activate Janus kinase (JAK)–signal transducer
and activator of transcription (STAT) cascade, which further
induces angiogenesis, proliferation, and antiapoptotic pathways
in normal cells and favors cancer progression. We found
that both LEP and GH1 were upregulated in PMN-MDSCs,
compared with monocytic APCs (Figure 3A). Furthermore,
interleukin 5 (IL-5) and IL-22 were also upregulated in
PMN-MDSCs, which are the potent activators of STAT-3
(26, 27). Protein tyrosine phosphatase nonreceptor type 2
(PTPN2 or TC-PTP), a known phosphorylation inhibitor
of STAT1, STAT3, and STAT6 (28), was downregulated in
PMN-MDSCs (Figures 3A,B). Moreover, IL-5/GH1, potent
STAT3 activators, and STAT4 were upregulated in PMN-
MDSCs (Figures 3A,B). In addition, the signal transducing
adaptor molecule (STAM) gene, a known JAK signal accelerator
(29), was upregulated in PMN-MDSCs (Figures 3A,B).
Furthermore, PPI analysis showed that the vast majority of
genes related to JAK-STAT pathway formed a network from
10 genes. STRING database identified 10 nodes and 14 edges
with PPI enrichment P value 6.15e-07, average clustering
coefficient of 0.69, and average node degree of 2.8 (Figure 3C).
Collectively, these data suggest that the suppressive function
and protumorigenic effects of circulating PMN-MDSCs in
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FIGURE 2 | Comparative analyses of gene expression between PMN-MDSCs and monocytic APCs in the circulation of CRC patients. Hierarchical clustering of
PMN-MDSCs and monocytic APCs from four patients (7, 9, 12, and 16) on differentially expressed RNA transcripts from RNA-Seq data. Each column represents a
sample, and each row represents a transcript. The color gradient determines the expression level of each transcript (A). Volcano plot shows differentially expressed
genes; log2 fold change is plotted on the x-axis, and the statistical impact is shown on the y-axis. Fold changes with significant P values (>0.05) are highlighted in red
(for upregulated genes) and green (for downregulated genes) (B). Functional categorizations of significantly upregulated or downregulated genes were analyzed using
DAVID platform. Bar diagram illustrates the percentage of genes in each functional category (C). Heat maps show the Z score of upregulated (D) and downregulated
(E) transcripts in PMN-MDSCs, compared with monocytic APCs. Color codes are shown; red indicates upregulation, white indicates no change, and blue indicates
downregulation.
CRC could be associated with the upregulation of JAK-
STAT pathway, activation of DNA damage cascade, and the
downregulation of genes promoting tumor cell apoptosis
and myeloid cell maturation. Moreover, our data imply that
epigenetic modifications including histone acetylation could be
involved in the transcriptional regulation of genes in circulating
PMN-MDSCs of CRC patients.
Genes Associated With Acetylation Were
Upregulated in Circulating PMN-MDSCs,
Compared With I-MDSCs
Next, we compared the transcriptomic profiles of PMN-MDSCs
with I-MDSCs from three CRC patients (No. 7, 12, and
16). Sample 9 was not included in the analysis because of
asymmetric clustering with other three samples. Hierarchical
clustering of differentially expressed transcripts of PMN-MDSCs
and I-MDSCs is shown in Figure 4A. There were 1,087
transcripts found to be upregulated and 861 downregulated
in PMN-MDSCs, compared with I-MDSCs (FC >2 and P
< 0.05) (Figures 4A,B). We found that 179 genes related to
acetylation were upregulated in PMN-MDSCs, compared with
I-MDSCs. Additionally, genes related to DNA damage (29
genes), apoptosis (14 genes), DNA repair (6 genes), MAPK
signaling (11 genes), Wnt signaling (4 genes), and TGF-
β signaling (6 genes) pathways were upregulated in PMN-
MDSCs (Figures 4C,D;Table 2). It has been reported that TGF-β
signaling pathway could activate MAPK signaling cascade and
favors tumor progression (30). Interestingly, we found that TGF-
β signaling–related genes including PDGFB, KLF10, and TGFB3
and MAPK-related genes including DUSP7, BRAF, CRBB3,
and DAB2IP were significantly upregulated in PMN-MDSCs
(Figure 4D). These data suggest that enhanced TGF-β signaling
in PMN-MDSCs could activate MAPK signaling pathways for
the survival and progression of CRC. On the other hand, 101
genes related to translational regulation were downregulated
in PMN-MDSCs, compared with I-MDSCs (Figures 4C,E;
Table 2). This latter finding suggests that genes involved in
posttranslation modifications could be more important in PMN-
MDSC function.
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TABLE 2 | Summary of differentially regulated pathways in each group comparisons.
Group comparison Upregulated pathways Downregulated pathways
PMN-MDSCs vs. monocytic
APCs
JAK-STAT signaling,
DNA damage, chemotaxis, regulation of transcription, signal
transduction, cellular defense response, histone H4 acetylation
Apoptotic process, myeloid cell differentiation, MAPK activity,
negative regulation of transcription, Wnt signaling, DNA repair
PMN-MDSCs vs. I-MDSCs DNA damage, methyl transferase activity, acetylation, apoptosis,
DNA repair, MAPK signaling, Wnt signaling, and TGF-β signaling
Translational regulation, transcriptional regulation, IL-2, and IL-12
signaling
M-MDSCs vs. monocytic
APCs
Transcription factor binding, PI3P binding, PI3K activation, protein
dephosphorylation, regulation of transcription, apoptosis, histone
H3 acetylation, T-cell proliferation, myeloid cell differentiation, IL-6
signaling, and TGF-β signaling
IFN-γ signaling, immune system regulation, and peptidyl-tyrosine
dephosphorylation
I-MDSCs vs. monocytic
APCs
Cell cycle and protein phosphorylation Transcriptional coactivator activity, T-cell receptor signaling,
positive regulation of transcription, and cell migration
FIGURE 3 | JAK-STAT modulating genes in PMN-MDSCs in the circulation of CRC patients. Heat map shows the Z score of JAK-STAT pathway-related transcripts
that were downregulated/upregulated in PMN-MDSCs compared with monocytic APCs (A). KEGG pathway analysis, using DAVID, showed genes (marked with red
stars) involved in the JAK-STAT pathway (B). PPI network analyses using the STRING database of genes from significantly deregulated genes related to JAK-STAT
signaling pathway (C). GO ontologies (color coded), description, and false discovery rate (FDR) using the whole transcriptome as reference are stated for each
subnetwork. The overall network statistics are shown in the boxes.
Genes Associated With Apoptosis and
Transcriptional Regulations Were
Upregulated in Circulating M-MDSCs,
Compared With Monocytic APCs of CRC
Patients
Next, we compared the transcriptomic profiles of circulating
M-MDSCs and monocytic APCs from two CRC patients
(No. 7 and 16). The hierarchal clustering of differentially
expressed transcripts of M-MDSCs and monocytic APCs is
shown in Figure 5A. There were 1,719 transcripts found to be
upregulated and 371 downregulated in M-MDSCs, compared
with those found in monocytic APCs (FC >2 and P < 0.05)
(Figures 5A,B). PCAs of the total data sets confirmed the close
relativeness of biological replicates (Supplementary Figure 1B).
Functional annotation analyses showed that transcription factor
binding (35 genes)–, PI3P (7 genes)–, PI3K activation (3
genes)–, protein dephosphorylation (20 genes)–, transcriptional
regulation (155 genes)–, apoptosis (59 genes)–, histone H3
acetylation (8 genes)–, and IL-6 pathway (5 genes)–related genes
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FIGURE 4 | Comparative analyses of gene expression between PMN-MDSCs and I-MDSCs in the circulation of CRC patients. Hierarchical clustering of PMN-MDSCs
and I-MDSCs from three patients (07, 12, and 16) on differentially expressed transcripts. Expression level of each gene is illustrated as a color code (A). Volcano plot
illustrates the differential expression data, represented as log2 fold change on the x-axis, with the statistical impact on the y-axis. Fold changes with significant P
values (>0.05) are highlighted in red (for upregulated genes) and green (for downregulated genes) (B). Functional categorizations for significantly upregulated and
downregulated transcripts were analyzed on DAVID platform. Bar diagram illustrates the percentage of genes in each functional category (C). Heat maps show the Z
score of the upregulated (D) and downregulated (E) transcripts in PMN-MDSCs, compared with I-MDSCs, based on their functional categorization.
were upregulated in M-MDSCs, compared with monocytic
APCs (Figures 5C,D; Table 2). Additionally, our PPI network
analyses showed that there is a significant enrichment of genes
related to IL-6 pathway including five nodes and three edges
with PPI enrichment P = 0.000605 (Supplementary Figure 2B).
Notably, genes related to interferon γ (IFN-γ) (SLC11A1,
CD3E, IRF8, and CD226) and immune regulation (SIAE
and GGT1) were downregulated in M-MDSCs (Figures 5C,E).
It has been reported that STAT1/IFN-γ signaling pathway
was regulated by a novel tumor suppressor protein, IRF8
(31). Moreover, downregulation of IRF8 was evident in
breast tumor conditions leading to the progression of disease
(31). In agreement with this, we found that IRF8 was
significantly downregulated in M-MDSCs, which could be
the potent rationale for the downregulation of immune
regulation–related genes (Figure 5E). These results suggest that
circulating M-MDSCs could contribute to CRC progression
by suppressing the gene expression of immune-regulatory
molecules involved in the activation of immune responses
and upregulating genes involved in histone acetylation and
transcriptional regulation.
Genes Associated With Cell Migration and
Transcriptional Regulations Were
Downregulated in Circulating I-MDSCs,
Compared With Monocytic APCs of CRC
Patients
We then compared the transcriptomic profiles of I-MDSCs
with monocytic APCs from two CRC patients (No. 7 and
16). The differentially expressed transcripts are shown as
distinct cluster of I-MDSCs and monocytic APCs (Figure 6A).
One hundred twenty-nine transcripts were found to be
upregulated, and 275 were downregulated in I-MDSCs,
compared with those found in monocytic APCs (FC >2
and P < 0.05) (Figures 6A,B). PCAs of the total data
sets confirmed the close relativeness of biological replicates
(Supplementary Figure 1C). Functional annotation analyses
showed that cell cycle (8 genes)– and protein phosphorylation
(8 genes)–related genes were upregulated (Figures 6C,D),
and transcriptional (30 genes)– and cell migration (6 genes)–
related genes were downregulated in I-MDSCs (Figures 6C,E;
Table 2).
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FIGURE 5 | Comparative analyses of gene expression between M-MDSCs and monocytic APCs in the circulation of CRC patients. Hierarchical clustering of
M-MDSCs and monocytic APCs from two patients (07 and 16) on differentially expressed transcripts. Gene expression level is illustrated as a color code (A). Volcano
plot illustrates the differential expression data, represented as log2 fold change on the x-axis, with the statistical impact on the y-axis. Fold changes with significant P
values (>0.05) are highlighted in red (for upregulated genes) and green (for downregulated genes) (B). Functional categorizations for significantly upregulated and
downregulated transcripts were analyzed on DAVID platform. Bar diagram illustrates the percentage of genes in each functional category (C). Heat maps show the Z
score of the upregulated (D) and downregulated (E) transcripts in M-MDSCs, compared with monocytic APCs, based on their functional categorization.
Genes Associated With Acetylation Are
Upregulated in PMN-MDSCs and
M-MDSCs in the Circulation of CRC
Patients
Finally, we compared the common pathways, which were
upregulated/downregulated in PMN-MDSCs, M-MDSCs, and
I-MDSCs in the circulation of CRC patients. We found that
by comparing PMN-MDSCs vs. monocytic APCs, M-MDSCs
vs. monocytic APCs, and PMN-MDSCs vs. I-MDSCs, genes
related to acetylation were upregulated in PMN-MDSCs and
M-MDSCs (Figure 7A), and also genes related to apoptosis
and myeloid cell differentiation were upregulated in PMN-
MDSCs and M-MDSCs (Figure 7A). Moreover, transcriptional
regulation–related genes were upregulated in PMN-MDSCs and
M-MDSCs; when comparing PMN-MDSCs vs. monocytic APCs
and M-MDSCs vs. monocytic APCs (Figure 7A), DNA damage–
related genes were upregulated in PMN-MDSCs, compared
to monocytic APCs and I-MDSCs (Figure 7A). On the other
hand, protein phosphorylation–related genes were upregulated
in both I-MDSCs and M-MDSCs, compared to their controls
(Figure 7A). In the downregulated pathways panel, genes related
to transcription were downregulated in PMN-MDSCs and I-
MDSCs, when comparing PMN-MDSCs vs. monocytic APCs,
I-MDSCs vs. monocytic APCs, and PMN-MDSCs vs. I-MDSCs
(Figure 7B).
DISCUSSION
In this study, we performed comparative analyses on
transcriptomic profiles of different myeloid cell subsets in
the circulation of CRC patients. We found that various signaling
pathways, including JAK-STAT, chemotaxis, and histone
acetylation, were upregulated in PMN-MDSCs compared
with monocytic APC: PI3P kinase, PI3 kinase, apoptosis, H3
acetylation, IL-6, and TGF-β pathways were upregulated in
M-MDSCs, and cell cycle–related pathways were upregulated in
I-MDSCs compared with monocytic APCs.
Tumor-infiltrating inflammatory cells are reported to be
associated with disease progression; however, the functional
impact of particular subpopulations remains not evident (32).
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FIGURE 6 | Comparative analyses of gene expression between I-MDSCs and monocytic APCs in the circulation of CRC patients. Hierarchical clustering of I-MDSCs
and monocytic APCs from two patients (07 and 16) on differentially expressed transcripts. Expression level of each gene is illustrated as a color code (A). Volcano plot
illustrates the differential expression data, represented as log2 fold change on the x-axis, with the statistical impact on the y-axis. Fold changes with significant P
values (>0.05) are highlighted in red (for upregulated genes) and green (for downregulated genes) (B). Functional categorizations for significantly upregulated and
downregulated transcripts were analyzed on DAVID platform. Bar diagram illustrates the percentage of genes in each functional category (C). Heat maps show Z
score of the upregulated (D) and downregulated (E) transcripts in I-MDSCs, compared with monocytic APCs, based on their functional categorization.
Recently, we have reported that in the CRC TME, levels
of PMN-MDSCs, and I-MDSCs were higher compared with
M-MDSCs (18). Other than CRC, in lung cancer patients,
it has been reported that PMN-MDSCs accumulated in the
advanced stages have predominant suppressive characteristics
and favor tumor progression (33). We have previously shown
that various epigenetic-related genes including DNAmethylation
and HDACs were upregulated, and acetylation-related genes
were downregulated in colorectal tumor-infiltrating I-MDSCs,
compared with monocytic APCs (18). Notably, in the present
study, we found that acetylation-related genes were upregulated
in PMN-MDSCs, compared with monocytic APCs, in circulation
of CRC patients. Furthermore, in the CRC TME, DNA
methylation and HDACs were downregulated in PMN-MDSCs,
compared with monocytic APCs (18). In line with these
data, we found that histone acetylation– and transcription
regulation–related genes were upregulated in circulating PMN-
MDSCs. These data show that transcriptional regulation of
pivotal genes in circulating PMN-MDSCs might be regulated
by posttranslational histone modifications. Moreover, our
work showed that MAPK signaling and Wnt pathways were
upregulated in PMN-MDSCs of both TME (18) and circulation,
compared with I-MDSCs.
Tumor-infiltrating immune cells, including myeloid cells,
provide an immune-subversive environment for tumor
development and progression through the activation of various
signaling cascades (34). It has been reported that the MDSC
subset, I-MDSCs, favors tumor progression by expanding TH17
cells within the TME, rather than suppressing T cells (35). We
found that critical pathways for tumor progression associated
with DNA damage, MAPK, and Wnt signaling were upregulated
in PMN-MDSCs, compared with I-MDSCs. Interestingly,
JAK-STAT pathway was also found to be upregulated in
PMN-MDSCs, compared with monocytic APCs. JAK-STAT
pathway is one of the predominant signaling cascades, which
can promote immune suppression and tumor cell survival
(36). JAK-STAT signaling cascade has been implicated in the
induction of chemotaxis, which in turn triggers migratory
Frontiers in Oncology | www.frontiersin.org 9 September 2020 | Volume 10 | Article 1530
Sasidharan Nair et al. Transcriptomic Profiling of Circulating MDSCs
FIGURE 7 | Analyses of overlapping functional pathways between PMN-MDSCs, I-MDSCs, and M-MDSCs. Venn diagram summarizing the overlap between
functional pathways, which were upregulated (A) and downregulated (B) in the comparative analyses between PMN-MDSCs vs. monocytic APCs, PMN-MDSCs vs.
I-MDSCs, M-MDSCs vs. monocytic APCs, and I-MDSCs vs. monocytic APCs. Shared pathways are indicated by the overlap between circles.
signals in epithelial cells causing cell transformation from being
static epithelial cells to migratory cells (37). Interestingly, we
found that STAT3- and STAT4-related genes were upregulated
in circulating PMN-MDSCs, compared with monocytic
APCs. Reports showed that growth hormone induces the
activation of Hrs–STAM complex, which could enhance the
formation of JAK–receptor complexes (29, 38). In agreement
with these reports, we found that GH1 and STAM were
upregulated in PMN-MDSCs, compared with monocytic APCs.
Aberrant activation of JAK-STAT signaling pathway could also
activate MAPK pathway, which controls various fundamental
cellular processes that promote tumorigenesis, including cell
proliferation, survival, differentiation, and migration (39, 40).
Furthermore, components of the JAK-STAT signaling pathway
and its downstream cascade MAPK pathway could induce
regulatory T cell (Treg) and MDSC expansion and interfere
with TH1 differentiation (41, 42). Collectively, these data imply
that JAK-STAT signaling pathway in circulating PMN-MDSCs
could be important for triggering their own proliferation and
Treg expansion, contributing to malignant cell migration and
metastasis, and possibly opposing TH1 differentiation and
migration into the TME of CRC patients (43).
One of the most frequently altered pathways in human
cancer is the PI3K pathway, which has a critical role in
tumorigenesis and tumor progression (44). Here, we found
that PI3K and PI3P pathways were upregulated in M-MDSCs,
compared with monocytic APCs, which could activate multiple
downstream pathways and favor malignant cell progression. It
has been reported that the activation of PI3K could trigger
PI3P signaling cascade and promote the survival of tumor cells
(45). Additionally, genes related to IL-6 and TGF-β signaling
pathways were found to be upregulated in M-MDSCs, compared
to monocytic APCs. Overexpression of TGF-β has been reported
to promote tumorigenesis as it induces multiple non-Smad
pathways, which could reprogram epithelial cells and induce
epithelial–mesenchymal transition (46). This overexpression of
TGF-β was correlated with advanced disease stages, metastasis,
and poor prognosis in many cancer types, including CRC
(46–49). Moreover, TGF-β released by MDSCs can stimulate
Treg expansion and survival and enhance their suppressive
activity (50, 51). In turn, Tregs can trigger the induction of
MDSCs, thereby creating a positive feedback loop, favoring
immune suppression and T effector cell (Teff) apoptosis or
inactivation (50, 52). Reports showed that several non-Smad
signaling pathways could be activated by TGF-β, such as
PI3K/AKT and IL-6 signaling, leading to resistance to various
cancer treatments (47, 53, 54). These data suggest that M-
MDSCs in the circulation of CRC patients upregulate multiple
pathways, including TGF-β, IL-6, PI3P, and PI3K, which could
promote tumorigenesis by supporting Treg expansion and
suppressive activity and favoring immune suppression and
therapy resistance.
Signaling cascades are regulated by protein kinases, which
are activated or deactivated through phosphorylation and
dephosphorylation. Here, we found that, in I-MDSCs, both
cell cycle– and protein phosphorylation–related genes were
upregulated, compared with monocytic APCs. These genes could
be associated with the activation of signaling cascades, which
govern cellular processes, such as cell proliferation, migration,
differentiation, survival, and growth of immune-suppressive
cells, and regulating Teff function and migration into the
TME (55).
Epigenetic modifications via DNA methylation and
histone methylation/acetylation have also a major impact
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on tumorigenesis, immunosuppression, and cancer progression
(18, 56, 57). Additionally, acetylation and deacetylation of both
histone and nonhistone marks have been reported to be closely
associated with the transcriptomic regulation of genes associated
with cell proliferation, cell cycle, and apoptosis in cancer. Here,
we found that acetylation-related genes were upregulated in
PMN-MDSCs and M-MDSCs, compared with monocytic APCs.
Apart from acetylation, genes related to transcription, DNA
damage, apoptosis, and myeloid differentiation were also found
to be upregulated in PMN-MDSCs and M-MDSCs. These
data suggest that elevated expression of acetylation-related
genes in MDSCs could trigger multiple signaling cascades
promoting the survival and progression of malignant cells.
However, the suppressive function of these cells in human is not
totally evident.
Some of the signaling pathways investigated in this study
were exclusively upregulated in one myeloid suppressive
subset, implicating the importance of their functions and
contribution to CRC progression. Additionally, this study
revealed some of the epigenetic mechanisms, which control
the transcriptional profile of the different myeloid cell
subsets. However, further studies are required to validate
these findings using functional assays and in larger patient
cohorts. Additionally, it would be interesting to compare the
transcriptomic profiles of circulating MSDC subsets between
CRC patients and healthy donors to identify distinct enrichment
of transcripts/pathways in specific subsets favoring onset and
progression of CRC.
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